Search Results

Is liraglutide or exenatide better in type 2 diabetes?

Author: Doggrell, Sheila A

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 16, November 2009 , pp. 2769-2772(4)

Publisher: Informa Healthcare

New developments in incretin-based therapies: The current state of the field

Author: Robertson, Carolyn

Source: Journal of the American Academy of Nurse Practitioners, Volume 21, Supplement 1, November 2009 , pp. 631-641(11)

Publisher: Blackwell Publishing

Optimizing outcomes with incretin-based therapies: Practical information for nurse practitioners to share with patients

Author: Fleury-Milfort, Evelyne

Source: Journal of the American Academy of Nurse Practitioners, Volume 21, Supplement 1, November 2009 , pp. 642-650(9)

Publisher: Blackwell Publishing

Byetta label changed to include renal failure warnings

Source: Reactions, Volume 1, Number 1277, 2009-11-07 , pp. 5-5(1)

Publisher: Adis International

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

Authors: Brixner, D. I.; McAdam-Marx, C.; Ye, X.; Boye, K. S.; Nielsen, L. L.; Wintle, M.; Misurski, D.; Fabunmi, R.

Source: Diabetes, Obesity and Metabolism, Volume 11, Number 12, December 2009 , pp. 1122-1130(9)

Publisher: Blackwell Publishing

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics

Authors: Kazda, C.; Gallwitz, B.; Simó, R.; Guzmán, J. R.; Kraus, P.; Nicolay, C.; Rose, L.; Schernthaner, G.

Source: Diabetes, Obesity and Metabolism, Volume 11, Number 12, December 2009 , pp. 1131-1137(7)

Publisher: Blackwell Publishing

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

Authors: Davies, M. J.; Donnelly, R.; Barnett, A. H.; Jones, S.; Nicolay, C.; Kilcoyne, A.

Source: Diabetes, Obesity and Metabolism, Volume 11, Number 12, December 2009 , pp. 1153-1162(10)

Publisher: Blackwell Publishing

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

Authors: McAdam-Marx, C.; Ye, X.; Brixner, D. I.; Fabunmi, R.; Wintle, M.; Boye, K. S.; Misurski, D.; Nielsen, L. L.

Source: Diabetes, Obesity and Metabolism, Volume 11, Number 12, December 2009 , pp. 1173-1174(2)

Publisher: Blackwell Publishing

A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin Glargine

Authors: Misurski, Derek; Lage, Maureen J.; Fabunmi, Rosalind; Boye, Kristina S.

Source: Applied Health Economics and Health Policy, Volume 7, Number 4, 1 December 2009 , pp. 245-254(10)

Publisher: Adis International

Different Effects of FK506, Rapamycin, and Mycophenolate Mofetil on Glucose-Stimulated Insulin Release and Apoptosis in Human Islets

Authors: Johnson, James D.; Ao, Ziliang; Ao, Peter; Li, Hong; Dai, Long-Jun; He, Zehua; Tee, May; Potter, Kathryn J.; Klimek, Agnieszka M.; Meloche, R. Mark; Thompson, David M.; Verchere, C. Bruce; Warnock, Garth L.

Source: Cell Transplantation, Volume 18, Number 8, 2009 , pp. 833-845(13)

Publisher: Cognizant Communication Corporation

EASD studies shed light on costs of insulin initiation for T2DM

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 3-4(2)

Publisher: Adis International

Weekly exenatide demonstrates QOL superiority in T2DM

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 10-10(1)

Publisher: Adis International

The effects of glucagon-like peptide-1 on the beta cell

Author: Vilsbøll

Source: Diabetes, Obesity and Metabolism, Volume 11, Supplement 3, December 2009 , pp. 11-18(8)

Publisher: Blackwell Publishing

Exenatide: Acute pancreatitis: case report

Source: Reactions, Volume 1, Number 1276, 2009-10-31 , pp. 14-14(1)

Publisher: Adis International

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

Authors: Mittendorf, T.; Smith-Palmer, J.; Timlin, L.; Happich, M.; Goodall, G.

Source: Diabetes, Obesity and Metabolism, Volume 11, Number 11, November 2009 , pp. 1068-1079(12)

Publisher: Blackwell Publishing

Exenatide and sitagliptin appear to carry no higher risk of acute pancreatitis than metformin or glibenclamide [glyburide]

Source: Reactions, Volume 1, Number 1273, 2009-10-10 , pp. 5-5(1)

Publisher: Adis International

Exenatide trumps insulin glargine in cost effectiveness

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 586, 2009-09-05 , pp. 1-1(1)

Publisher: Adis International

Exenatide efficacy and safety: a systematic review

Authors: Norris, S. L.; Lee, N.; Thakurta, S.; Chan, B. K. S.

Source: Diabetic Medicine, Volume 26, Number 9, September 2009 , pp. 837-846(10)

Publisher: Blackwell Publishing

Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus

Authors: Paisley, A. N.; Savage, M. W.; Wiles, P. G.

Source: Diabetic Medicine, Volume 26, Number 9, September 2009 , pp. 935-938(4)

Publisher: Blackwell Publishing

Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?

Authors: Ahluwalia, R.; Perkins, K.; Ewins, D.; Goenka, N.

Source: Diabetic Medicine, Volume 26, Number 8, August 2009 , pp. 834-835(2)

Publisher: Blackwell Publishing